ET
The startup develops a retinal treatment technology that utilizes suprachoroidal injection for targeted drug delivery, addressing the challenges of effective distribution within the eye. This method aims to enhance patient compliance and improve therapeutic outcomes through sustained drug release.
Updated 3 months ago
Funding
$950K raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
Funding rounds are not available yet.
Founders
Product
Features
- The startup develops a retinal treatment technology that utilizes suprachoroidal injection for targeted drug delivery, addressing the challenges of effective distribution within the eye. This method aims to enhance patient compliance and improve therapeutic outcomes through sustained drug release.